Related Experiment Videos

Successful control with bromide of two patients with malignant migrating partial seizures in infancy

K Okuda1, A Yasuhara, A Kamei

  • 1Department of Pediatrics, Kansai Medical University, Moriguchi, Japan.

Brain & Development
|April 13, 2000
PubMed

Insights

Potassium bromide effectively treated malignant migrating partial seizures in infancy (MMPSI), a severe epilepsy condition. This treatment led to complete seizure control in one infant and significant reduction in another.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Clinical Pharmacology

Background:

  • Malignant migrating partial seizures in infancy (MMPSI) is a rare and severe form of epilepsy characterized by intractable seizures and developmental arrest.
  • Conventional antiepileptic drugs often prove ineffective in managing MMPSI, necessitating exploration of alternative therapeutic strategies.

Observation:

  • Two infants, a 3-month-old male and a 4-month-old female, presented with intractable seizures and were diagnosed with MMPSI based on clinical symptoms, disease progression, and EEG findings.
  • Standard antiepileptic treatments failed to provide adequate seizure control in both patients.

Findings:

  • Treatment with potassium bromide at a dosage of 80 mg/kg was administered to both infants after the failure of conventional therapies.
  • Potassium bromide therapy resulted in complete cessation of seizures in one infant and a reduction of over 95% in seizure frequency in the other.

Implications:

  • Potassium bromide demonstrates significant efficacy as a therapeutic option for infants diagnosed with malignant migrating partial seizures in infancy.
  • This finding suggests that potassium bromide may be a valuable addition to the treatment armamentarium for refractory infantile epilepsy syndromes.
  • Further research is warranted to establish optimal dosing, long-term efficacy, and safety profiles of potassium bromide in this pediatric population.

Related Concept Videos